Abstract 2453
Background
VELOUR trial compared FOLFIRI+/-aflibercept in 1226 mCRC patients after progression to oxaliplatin-based treatment, regardless of biological previous therapies. mOS (13.50 vs 12.06 months) and mPFS (6.90 vs 4.67 months) were increased, which led to aflibercept approval. We do not have yet enough information on aflibercept after anti-EGFR treatment. Our goal was to analyze efficacy and safety data of aflibercept in this specific context.
Methods
Retrospective analysis of clinical, therapeutic, and survival data collected from 120 consecutive RASwt mCRC patients treated from 2012 to 2017 with FOLFIRI-aflibercept after progression to standard chemotherapy + anti-EGFR in 12 Spanish hospitals.
Results
Median age was 60, 62.5% male, 37.5% female. 24% were right-sided tumours and 76% left-sided, with primary tumour resection in 41%. 100% RASwt, 5% BRAFmt. All patients received prior anti-EGFR therapy and 96% had ECOG 0/1. Median of FOLFIRI-Aflibercept cycles was 12, with 33% ORR. mPFS was 6.9 months (95% CI 6.0-7.7). BRAF, ECOG, primary tumour resection and nº of metastatic sites had statistical significance in univariate analysis; and primary tumour resection was also significant in multivariate analysis. mOS was 14.5 months (95% CI 9.7-19.3), with statistical significance in univariate for primary tumour resection, ECOG, and nº of metastatic sites. ECOG and nº of metastatic sites reached significance in multivariate analysis. As for toxicity, only 18.3% needed aflibercept dose reduction. 2nd line treatment was discontinued in 71.8% (mostly due to progression: 51.7%, 6.7% toxicity,1.7% surgery). 37% reached G3-4 toxicity (16.6% hematologic, 7.5% HTN, 5.9% asthenia, 2.5% perforation) 59% received a 3rd line therapy: 23% TAS-102, 18% regorafenib, 9% capecitabine.
Conclusions
RASwt mCRC patients reached similar results to those reported in VELOUR trial. The efficacy of subsequent aflibercept-containing 2nd line was maintained regardless of prior anti-EGFR. The efficacy of subsequent aflibercept-containing 2nd line was maintained regardless of prior anti-EGFR. Our results suggest that FOLFIRI-aflibercept, after 1st line with anti-EGFR, is a good treatment strategy for RASwt mCRC.
Clinical trial identification
Legal entity responsible for the study
Ruth Vera García.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract